Follow-up
Follow-up information was obtained regularly in an outpatient clinic. Telephone contacts to patients, physicians, and the next of kin were performed every 6 months. The follow-up time was started after completion of the treatment. The endpoint of the study was grade 3–4 cardiovascular adverse events (CAEs) including cardiac death, symptomatic heart failure, arrhythmia, Subclinical Cardiac dysfunction with the use of established toxicity grading system to quantify the severity of the adverse events (the Common Terminology Criteria for Adverse Events [CTCAE] of the US National Cancer Institute).